Pharmacogenomics and Adverse Drug Reactions

Pharmacogenomics studies how inherited genetic variation shapes individual responses to drugs, including the risk of adverse reactions. Variants in drug-metabolising enzymes, transporters, and immune (HLA) genes help explain why a dose that is safe for most people harms a few. This field turns part of the otherwise unpredictable Type B reaction into something that can, for specific drug-gene pairs, be anticipated and avoided.

Definition

Pharmacogenomics of adverse drug reactions is the study of how heritable variation in genes affecting drug disposition, drug targets, and immune recognition influences an individual's susceptibility to harmful drug effects, with the aim of predicting and preventing such reactions.

Scope

The topic covers the genetic determinants of adverse drug reactions: pharmacokinetic variation in metabolising enzymes and transporters, immune-genetic (HLA) associations with severe hypersensitivity, the evidence for pre-treatment genetic screening, and the consortia that translate findings into actionable recommendations. It is a reference and educational entry; it describes the science of susceptibility and does not give individualised testing or prescribing advice.

Core questions

• How do genetic variants in drug-metabolising enzymes alter the risk of toxicity?
• Why are particular HLA alleles linked to specific severe drug reactions?
• What evidence supports pre-treatment genetic screening to prevent harm?
• How are drug-gene associations translated into clinical recommendations?

Key concepts

• Pharmacokinetic gene variation (e.g. metabolising enzymes, transporters)
• Poor, intermediate, and ultrarapid metaboliser phenotypes
• HLA-associated hypersensitivity
• Drug-gene pairs
• Pre-emptive and reactive genotyping
• Susceptibility (the S in DoTS)
• Clinical implementation consortia

Mechanisms

Genetic variation contributes to adverse reactions through two broad routes. Pharmacokinetic variants in drug-metabolising enzymes and transporters change how much active drug or toxic metabolite reaches tissues, so that poor metabolisers may accumulate a drug to toxic levels while ultrarapid metabolisers may overproduce an active metabolite. Immune-genetic variants, chiefly in the HLA region, alter how drugs are presented to T cells and underlie several severe hypersensitivity reactions, consistent with the T-cell mechanisms of delayed drug allergy (Pichler, 2007). These genetic determinants explain part of the susceptibility that classification frameworks recognise but cannot otherwise specify (Edwards & Aronson, 2000).

Clinical relevance

For certain drug-gene pairs, identifying carriers before treatment can prevent serious reactions: randomised evidence shows that screening for HLA-B*57:01 prevents abacavir hypersensitivity (Mallal et al., 2008). Consortia synthesise such evidence into structured recommendations for how genotype information could inform prescribing (Relling & Klein, 2011). This entry describes the evidence and mechanisms as reference knowledge and is not a substitute for clinical genetic-testing or prescribing guidance.

Epidemiology

The clinical value of a marker depends on how strongly it predicts the reaction and how common both the variant and the reaction are. HLA associations and their utility vary by drug and by ancestry, so the populations in which screening is informative differ accordingly (Mallal et al., 2008).

Evidence & guidelines

The strongest evidence base is the randomised demonstration of HLA-B*57:01 screening for abacavir (Mallal et al., 2008). Translation into practice is coordinated by the Clinical Pharmacogenetics Implementation Consortium, which publishes drug-gene recommendations to guide how validated genotype results may be used (Relling & Klein, 2011).

History

Pharmacogenetics emerged in the mid-twentieth century from observations of inherited differences in drug metabolism, and the genomic era expanded it into pharmacogenomics. Landmark genetic associations with severe drug reactions -- including HLA-B*57:01 with abacavir hypersensitivity, confirmed prospectively in 2008 -- established that some Type B reactions are genetically predictable (Mallal et al., 2008). The founding of implementation consortia such as CPIC marked the shift from discovery to structured clinical translation (Relling & Klein, 2011).

Debates

Should genotyping be pre-emptive or reactive?

Testing a single drug-gene pair only when a drug is about to be prescribed (reactive) is targeted but can delay treatment, whereas testing a panel in advance (pre-emptive) makes results available when needed but raises questions of cost, interpretation, and incidental findings; the optimal approach is still debated.

Key figures

• Munir Pirmohamed
• Mary V. Relling
• Teri E. Klein
• Simon Mallal
• Elizabeth Phillips

Seminal works

• mallal-2008
• relling-klein-2011

Frequently asked questions

Can a genetic test predict every adverse drug reaction?

No. Genetic markers strongly predict only a limited set of well-characterised drug-gene pairs, such as HLA-B*57:01 and abacavir. Most adverse reactions involve multiple genetic and non-genetic factors and are not captured by a single test.

Why does pharmacogenomic risk differ between populations?

The frequency of relevant variants, including HLA alleles, differs across ancestral populations, so a marker that usefully predicts a reaction in one group may be rare or less informative in another. Recommendations therefore can be population-specific.